Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.480
+0.010 (0.22%)
At close: May 15, 2026, 4:00 PM EDT
4.560
+0.080 (1.79%)
After-hours: May 15, 2026, 6:59 PM EDT
Prelude Therapeutics Employees
Prelude Therapeutics had 79 employees as of December 31, 2025. The number of employees decreased by 52 or -39.69% compared to the previous year.
Employees
79
Change (1Y)
-52
Growth (1Y)
-39.69%
Revenue / Employee
$211,646
Profits / Employee
-$984,785
Market Cap
450.59M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 79 | -52 | -39.69% |
| Dec 31, 2024 | 131 | 3 | 2.34% |
| Dec 31, 2023 | 128 | 6 | 4.92% |
| Dec 31, 2022 | 122 | 6 | 5.17% |
| Sep 30, 2022 | 120 | 7 | 6.19% |
| Jun 30, 2022 | 112 | 12 | 12.00% |
| Mar 31, 2022 | 118 | 13 | 12.38% |
| Dec 31, 2021 | 116 | 48 | 70.59% |
| Sep 30, 2021 | 113 | 58 | 105.45% |
| Jun 30, 2021 | 100 | 49 | 96.08% |
| Mar 31, 2021 | 105 | 54 | 105.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Lyell Immunopharma | 300 |
| ADC Therapeutics | 193 |
| Century Therapeutics | 78 |
| Lexeo Therapeutics | 59 |
| PureTech Health | 56 |
| Fulcrum Therapeutics | 55 |
| Eupraxia Pharmaceuticals | 49 |
PRLD News
- 2 days ago - Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs - TheFly
- 4 days ago - Prelude Therapeutics reports Q1 EPS (13c), consensus (27c) - TheFly
- 5 days ago - Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 13 days ago - Prelude Therapeutics initiated with a Buy at D. Boral Capital - TheFly
- 19 days ago - Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright - TheFly
- 27 days ago - Prelude Therapeutics presents new preclinical data from PRT13722 study - TheFly
- 27 days ago - Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering - GlobeNewsWire
- 27 days ago - Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire